课题基金 / 基金详情

PROAB3004: SAFETY, EFFICACY & PK 0F 141W94 + CURRENT RX IN HIV+ CHILDREN

PROAB3004: SAFETY, EFFICACY & PK 0F 141W94 + CURRENT RX IN HIV+ CHILDREN
PROAB3004：安全性、有效性
批准号：
6264599
负责人：
William Borkowsky
金额：
$2.1万
依托单位：
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
依托单位国家：
美国
项目类别：
财政年份：
1998
资助国家：
美国
项目状态：
已结题
起止时间：
1998-12-01 至 1999-11-30
来源：
https://reporter.nih.gov/project-details/6264599
关键词：
HIV infections adolescence (12-20) antiAIDS agent child (0-11) clinical research combination chemotherapy drug adverse effect human subject human therapy evaluation pediatric AIDS pediatric pharmacology pharmacokinetics protease inhibitor reverse transcriptase inhibitors sulfonamides virus RNA

项目摘要

项目成果

William Borkowsky的其他基金

相关文献

中文摘要
翻译
这项开放标签单组非比较试验的主要目的是评价141 W 94在HIV感染的儿科受试者（4-18岁）中至少48周的安全性和耐受性，并根据血浆HIV RNA水平确定141 W 94联合当前抗逆转录病毒治疗的抗病毒作用。 本研究还旨在评估141 W 94联合两种核苷逆转录酶抑制剂在HIV-1感染儿童中的药代动力学。
英文摘要
The primary objectives of this open label single arm noncomparative trial are to evaluate the safety and tolerability of 141W 94 in HIV-infected pediatric subjects (ages 4-18) for a minimum 48 week period and to determine the antiviral effect of 141W94 in combination with current antiretroviral therapy, based on plasma HIV RNA levels. The study is also designed to assess the pharmacokinetics of 141W94 in combination with two nucleoside reverse transcriptase inhibitors in HIV-1 infected children.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Virology Core
CLINICAL TRIAL: PACTG 390: ANTIRETROVIRAL REGIMENS AND TREATMENT-SWITCHING STRAT
CLINICAL TRIAL: PACTG 1020-A: NOVEL PROTEASE INHIBITOR (BMS-232632) IN HIV-INFEC
CLINICAL TRIAL: PACTG 1025: PERINATAL CORE PROTOCOL (AIDS)